<SEC-DOCUMENT>0001125345-17-000101.txt : 20171027
<SEC-HEADER>0001125345-17-000101.hdr.sgml : 20171027
<ACCEPTANCE-DATETIME>20171027165215
ACCESSION NUMBER:		0001125345-17-000101
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		4
CONFORMED PERIOD OF REPORT:	20171024
ITEM INFORMATION:		Entry into a Material Definitive Agreement
ITEM INFORMATION:		Regulation FD Disclosure
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20171027
DATE AS OF CHANGE:		20171027

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			MACROGENICS INC
		CENTRAL INDEX KEY:			0001125345
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-36112
		FILM NUMBER:		171159987

	BUSINESS ADDRESS:	
		STREET 1:		9704 MEDICAL CENTER DRIVE
		CITY:			Rockville
		STATE:			MD
		ZIP:			20850
		BUSINESS PHONE:		301-251-5172

	MAIL ADDRESS:	
		STREET 1:		9704 MEDICAL CENTER DRIVE
		CITY:			ROCKVILLE
		STATE:			MD
		ZIP:			20850
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>form8-k_incyte2017.htm
<DESCRIPTION>8-K
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
	<head>
		<!-- Document created using Wdesk 1 -->
		<!-- Copyright 2017 Workiva -->
		<title>Document</title>
	</head>
	<body style="font-family:Times New Roman;font-size:10pt;">
<div><a name="s2292fd198eb4470e86b032dff39693dd"></a></div><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:144%;text-align:center;-sec-extract:summary;font-size:14pt;"><font style="font-family:inherit;font-size:14pt;font-weight:bold;">UNITED STATES</font></div><div style="line-height:144%;text-align:center;font-size:14pt;"><font style="font-family:inherit;font-size:14pt;font-weight:bold;">SECURITIES AND EXCHANGE COMMISSION</font></div><div style="line-height:144%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:144%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">&#32;WASHINGTON, D.C. 20549</font></div><div style="line-height:144%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">____________________</font></div><div style="line-height:144%;text-align:center;font-size:18pt;"><font style="font-family:inherit;font-size:18pt;font-weight:bold;">FORM 8-K</font></div><div style="line-height:144%;text-align:center;font-size:18pt;"><font style="font-family:inherit;font-size:18pt;"><br></font></div><div style="line-height:144%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">CURRENT REPORT</font></div><div style="line-height:144%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:144%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">&#32;Pursuant to Section 13 or 15(d) of the</font></div><div style="line-height:144%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Securities Exchange Act of 1934</font></div><div style="line-height:144%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:144%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Date of report (Date of earliest event reported):&#160; October 24, 2017</font></div><div style="line-height:144%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:144%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">MACROGENICS, INC.</font></div><div style="line-height:144%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:144%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#32;(Exact Name of Registrant as Specified in Charter)</font></div><div style="line-height:120%;padding-bottom:9px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-left:4px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:35%;"></td><td style="width:30%;"></td><td style="width:35%;"></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:center;padding-left:4px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Delaware</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:center;padding-left:4px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">001-36112</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:center;padding-left:4px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">06-1591613</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-top:2px;text-align:center;padding-left:4px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(State or Other Jurisdiction</font></div><div style="padding-bottom:2px;text-align:center;padding-left:4px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">of Incorporation)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-top:2px;text-align:center;padding-left:4px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(Commission</font></div><div style="padding-bottom:2px;text-align:center;padding-left:4px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;File Number)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-top:2px;text-align:center;padding-left:4px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(IRS Employer</font></div><div style="padding-bottom:2px;text-align:center;padding-left:4px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;Identification No.)</font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:9px;padding-top:4px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-left:4px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="2"></td></tr><tr><td style="width:64%;"></td><td style="width:36%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-top:2px;text-align:center;padding-left:4px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">9704 Medical Center Drive,</font></div><div style="padding-bottom:2px;text-align:center;padding-left:4px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Rockville, Maryland</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:center;padding-left:4px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">20850</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:center;padding-left:4px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(Address of Principal Executive Offices)</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:center;padding-left:4px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(Zip Code)</font></div></td></tr></table></div></div><div style="line-height:144%;padding-top:4px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:144%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Registrant's telephone number, including area code:&#160; </font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">(301) 251-5172</font></div><div style="line-height:144%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:144%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Not applicable</font></div><div style="line-height:144%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:144%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(Former Name or Former Address, if Changed Since Last Report)</font></div><div style="line-height:144%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:144%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):</font></div><div style="line-height:144%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">[&#160; ] Written communications pursuant to Rule&#160;425 under the Securities Act (17 CFR 230.425)</font></div><div style="line-height:144%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">[&#160; ] Soliciting material pursuant to Rule&#160;14a-12 under the Exchange Act (17 CFR 240.14a-12)</font></div><div style="line-height:144%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">[&#160; ] Pre-commencement communications pursuant to Rule&#160;14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</font></div><div style="line-height:144%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">[&#160; ] Pre-commencement communications pursuant to Rule&#160;13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</font></div><div style="line-height:144%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 or Rule 12b-2 of the Securities Exchange Act of 1934.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Emerging growth company&#160;[&#160; ]</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div><br></div><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.&#160;[&#160; ]</font></div><div style="line-height:120%;padding-top:29px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;background-color:#ffffff;font-weight:bold;">Item 1.01 &#160;&#160;&#160;&#160;Entry into a Material Definitive Agreement</font></div><div style="line-height:120%;padding-top:16px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On&#160;October 24, 2017, MacroGenics, Inc. (the &#8220;Company&#8221;) entered into an exclusive global collaboration and license agreement (the &#8220;Agreement&#8221;) with Incyte Corporation (&#8220;Incyte&#8221;) for the Company&#8217;s MGA012 molecule, an investigational monoclonal antibody (mAb) that inhibits programmed cell death protein 1 (PD-1). Under the terms of the Agreement, Incyte has obtained exclusive worldwide rights from the Company for the development and commercialization of MGA012 in all indications, while the Company retains the right to develop its pipeline assets in combination with MGA012. Further, the Company retains the right to manufacture a portion of both companies&#8217; global clinical and commercial supply needs of MGA012.  The transaction is expected to close in the fourth quarter of 2017, subject to the early termination or expiration of any applicable waiting periods under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 and customary closing conditions.</font></div><div style="line-height:120%;padding-top:16px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#32;Upon closing, Incyte will pay the Company an upfront payment of $150 million.  The Company will also be eligible to receive up to an additional $750 million in potential clinical, regulatory and sales milestone payments related to MGA012. In addition, the Company will be eligible to receive royalty payments based on global net sales of MGA012 by Incyte.&#160;&#160;&#160;&#160;</font></div><div style="line-height:120%;padding-top:16px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The foregoing description of the Agreement is qualified in its entirety by reference to the Agreement, a copy of which will be filed as an exhibit to the Company&#8217;s Annual Report on Form 10-K for the year ending December 31, 2017.</font></div><div style="line-height:174%;padding-bottom:6px;padding-top:6px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:174%;padding-bottom:6px;padding-top:6px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Forward-Looking Statements</font></div><div style="line-height:120%;padding-bottom:8px;padding-top:16px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">This Current Report on Form 8-K contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. These include statements about future expectations, plans and prospects for the Company, including statements about the Company&#8217;s strategy, future operations, clinical development of its therapeutic candidates, milestone or opt-in payments from the Company&#8217;s collaborators, the Company&#8217;s anticipated milestones and future expectations and plans and prospects for the Company.  Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including: the uncertainties inherent in the initiation and enrollment of future clinical trials, expectations of expanding ongoing clinical trials, availability and timing of data from ongoing clinical trials, expectations for regulatory approvals, other matters that could affect the availability or commercial potential of the Company&#8217;s product candidates and other risks described in the Company&#8217;s filings with the Securities and Exchange Commission. In addition, the forward-looking statements included in this Current Report on Form 8-K represent the Company&#8217;s views only as of the date hereof. The Company anticipates that subsequent events and developments will cause the Company&#8217;s views to change. However, while the Company may elect to update these forward-looking statements at some point in the future, the Company specifically disclaims any obligation to do so, except as may be required by law. These forward-looking statements should not be relied upon as representing the Company&#8217;s views as of any date subsequent to the date hereof.</font></div><div style="line-height:120%;padding-top:29px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Item 7.01. </font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Regulation FD Disclosure. </font></div><div style="line-height:120%;padding-top:16px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On October 25, 2017, the Company issued a press release announcing the Agreement. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and incorporated by reference herein. </font></div><div style="line-height:120%;padding-top:16px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The information furnished pursuant to this Item 7.01 of this Report, including Exhibit 99.1 attached hereto, shall not be deemed &#8220;filed&#8221; for purposes of Section 18 of the Exchange Act or otherwise subject to the liability of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or under the Exchange Act, regardless of any general incorporation language in any such filing, unless the Company expressly sets forth in such filing that such information is to be considered &#8220;filed&#8221; or incorporated by reference therein. </font></div><div style="line-height:174%;padding-bottom:9px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:174%;padding-bottom:9px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><br></div><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:174%;padding-bottom:9px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Item 9.01</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Financial Statements and Exhibits</font></div><div style="line-height:174%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:174%;padding-bottom:9px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">(d) Exhibits.</font></div><div style="line-height:174%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:174%;padding-bottom:9px;padding-top:4px;text-align:left;text-indent:96px;font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="exhibit99-1_pressreleasein.htm"><font style="font-family:inherit;font-size:10pt;">99.1</font></a><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="exhibit99-1_pressreleasein.htm"><font style="font-family:inherit;font-size:10pt;">Press Release, dated October 25, 2017. </font></a></div><div style="line-height:174%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:174%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:144%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><br></div><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:144%;padding-bottom:4px;padding-top:4px;text-align:center;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">SIGNATURE</font></div><div style="line-height:144%;padding-bottom:4px;padding-top:4px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.</font></div><div style="line-height:120%;padding-bottom:13px;padding-top:4px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-left:4px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:49%;"></td><td style="width:7%;"></td><td style="width:44%;"></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:left;padding-left:4px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Date:&#160; October 27, 2017</font></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;padding-top:2px;padding-left:4px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">MACROGENICS, INC.</font></div><div style="padding-bottom:2px;padding-top:2px;padding-left:4px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="padding-bottom:2px;padding-top:2px;padding-left:4px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="padding-bottom:2px;padding-top:2px;padding-left:4px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:left;padding-left:4px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">By:</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-top:2px;padding-left:4px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">/s/ Jeffrey Peters</font></div><div style="padding-left:4px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Jeffrey Peters</font></div><div style="padding-bottom:2px;padding-left:4px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Vice President and Acting General Counsel</font></div></td></tr></table></div></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><br></div><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div>	</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>exhibit99-1_pressreleasein.htm
<DESCRIPTION>EXHIBIT 99.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
	<head>
		<!-- Document created using Wdesk 1 -->
		<!-- Copyright 2017 Workiva -->
		<title>Exhibit</title>
	</head>
	<body style="font-family:Times New Roman;font-size:10pt;">
<div><a name="s9F3B94D2D9288C7BE4775070D5A4D643"></a></div><div></div><div><br></div><div style="line-height:138%;padding-bottom:8px;text-align:center;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="2"></td></tr><tr><td style="width:50%;"></td><td style="width:50%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div><img src="exhibit991pressreleasimage2.jpg" alt="exhibit991pressreleasimage2.jpg" style="height:85px;width:124px;"></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-indent:144px;"><img src="exhibit991pressreleas_image1.jpg" alt="exhibit991pressreleas_image1.jpg" style="height:76px;width:136px;"></div></td></tr></table></div></div><div style="line-height:138%;padding-bottom:8px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:138%;padding-bottom:8px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;text-decoration:underline;">For Immediate Release</font></div><div style="line-height:138%;padding-bottom:8px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:138%;padding-bottom:16px;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Incyte and MacroGenics Announce Global Collaboration and Licensing Agreement for Anti-PD-1 Monoclonal Antibody MGA012 </font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:138%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:138%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Incyte gains exclusive, worldwide development and commercialization rights to MGA012 in all indications</font></div></td></tr></table><div style="line-height:138%;text-align:left;padding-left:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:138%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:138%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">MacroGenics to receive an upfront cash payment of $150 million plus potential milestone payments</font><font style="font-family:inherit;font-size:11pt;">&#32;</font><font style="font-family:inherit;font-size:10pt;font-style:italic;">and royalties, and retains right to develop its pipeline assets in combination with MGA012</font></div></td></tr></table><div style="line-height:138%;text-align:left;padding-left:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:138%;padding-bottom:8px;padding-top:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">WILMINGTON, Del. AND ROCKVILLE, Md. &#8211; October 25, 2017</font><font style="font-family:inherit;font-size:10pt;">&#32;&#8211; Incyte Corporation (NASDAQ:INCY) and MacroGenics, Inc. (NASDAQ:MGNX) announced today that the companies have entered into an exclusive global collaboration and license agreement for MacroGenics&#8217; MGA012, an investigational monoclonal antibody that inhibits programmed cell death protein 1 (PD-1). Incyte has obtained exclusive worldwide rights for the development and commercialization of MGA012 in all indications, while MacroGenics retains the right to develop its pipeline assets in combination with MGA012.</font></div><div style="line-height:138%;padding-bottom:13px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8220;Anti-PD-1 therapy is becoming a mainstay of cancer treatment across multiple tumor types, and we believe the addition of MGA012 to our clinical pipeline is important to fulfilling our long-term development strategy in immuno-oncology. This collaboration with MacroGenics will allow us to rapidly explore the potential clinical benefit of developing MGA012 as a monotherapy and also combining anti-PD-1 therapy with several of our existing portfolio assets,&#8221; said Steven Stein, M.D., Chief Medical Officer of Incyte.</font></div><div style="line-height:138%;padding-bottom:13px;padding-top:6px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">"We believe Incyte is the ideal partner for MGA012, given its immuno-oncology portfolio and dedication to researching and developing innovative and transformative cancer therapies and we hope that the combined resources of both companies will be able to significantly expand and accelerate the current development efforts for this promising molecule,&#8221; said Scott Koenig, M.D., Ph.D., President and Chief Executive Officer of MacroGenics. &#8220;Furthermore, we look forward to exploring the combination of MGA012 with multiple molecules in our own portfolio, including DART molecules for redirected T-cell killing, antibodies with enhanced effector function and ADCs, potentially to provide improved patient benefit.&#8221;</font></div><div style="line-height:138%;padding-bottom:13px;padding-top:6px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Enrollment in the dose escalation portion of the Phase 1 study of MGA012 has been completed and the molecule is currently being evaluated as monotherapy across four solid tumor types in the dose expansion portion of the study. Data from the dose escalation portion of the Phase 1 study have been accepted for poster presentation at the upcoming Society for Immunotherapy of Cancer (SITC) 32nd Annual Meeting in November 2017.</font></div><div><br></div><div></div><hr style="page-break-after:always"><div></div><div><br></div><div style="line-height:138%;padding-bottom:8px;padding-top:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Terms of the Collaboration</font><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">&#32;</font></div><div style="line-height:138%;padding-bottom:8px;padding-top:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Upon closing, Incyte will pay MacroGenics an upfront payment of $150 million. Incyte will receive worldwide rights to develop and commercialize MGA012 in all indications. </font></div><div style="line-height:138%;padding-bottom:13px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Per the terms of the collaboration, MacroGenics will also be eligible to receive up to $420 million in potential development and regulatory milestones, and up to $330 million in potential commercial milestones. If MGA012 is approved and commercialized, MacroGenics would be eligible to receive royalties, tiered from 15 percent to 24 percent, on future sales of MGA012 by Incyte.</font></div><div style="line-height:138%;padding-bottom:13px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Under the terms of the collaboration, Incyte will lead global development of MGA012. MacroGenics retains the right to develop its pipeline assets in combination with MGA012, with Incyte commercializing MGA012 and MacroGenics commercializing its asset(s), if any such potential combinations are approved.</font></div><div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In addition, MacroGenics retains the right to manufacture a portion of both companies&#8217; global clinical and commercial supply needs of MGA012. MacroGenics intends to utilize its commercial-scale GMP facility, which is expected to be fully operational in 2018. </font></div><div style="line-height:138%;padding-bottom:8px;padding-top:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The transaction is expected to close in the fourth quarter of 2017, subject to the early termination or expiration of any applicable waiting periods under the Hart-Scott Rodino Act and customary closing conditions.</font></div><div style="line-height:138%;padding-bottom:8px;padding-top:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">About Incyte Corporation</font></div><div style="line-height:138%;padding-bottom:8px;padding-top:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Incyte Corporation is a Wilmington, Delaware-based biopharmaceutical company focused on the discovery, development and commercialization of proprietary therapeutics. For additional information on Incyte, please visit the Company&#8217;s website at </font><font style="font-family:inherit;font-size:10pt;color:#0094ff;text-decoration:underline;">www.incyte.com</font><font style="font-family:inherit;font-size:10pt;">.</font></div><div style="line-height:138%;padding-bottom:8px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Follow @Incyte on Twitter at </font><font style="font-family:inherit;font-size:10pt;color:#0094ff;text-decoration:underline;">https://twitter.com/Incyte</font><font style="font-family:inherit;font-size:10pt;">. </font></div><div style="line-height:138%;padding-bottom:8px;padding-top:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">About MacroGenics, Inc.</font></div><div style="line-height:138%;padding-bottom:8px;padding-top:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">MacroGenics is a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer, as well as autoimmune disorders and infectious diseases. MacroGenics generates its pipeline of product candidates primarily from its proprietary suite of next-generation antibody-based technology platforms. The combination of MacroGenics' technology platforms and protein engineering expertise has allowed MacroGenics to generate promising product candidates and enter into several strategic collaborations with global pharmaceutical and biotechnology companies. For more information, please see MacroGenics&#8217; website at www.macrogenics.com. MacroGenics and the MacroGenics logo are trademarks or registered trademarks of MacroGenics, Inc.</font></div><div style="line-height:138%;padding-bottom:8px;padding-top:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Incyte Forward-Looking Statements </font></div><div style="line-height:138%;padding-bottom:8px;padding-top:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Except for the historical information set forth herein, the matters set forth in this press release contain predictions, estimates and other forward-looking statements, including without limitation statements regarding: whether the planned transaction will close within the expected timeframe or ever; whether MGA012 will successfully advance through clinical studies or will ever be approved for use in humans anywhere or will be commercialized anywhere successfully or at all; whether MGA012 will be effective in the treatment of cancer or other indications; and whether and when any of the milestone payments or royalties under this collaboration will ever be paid by Incyte. These forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially, including unanticipated developments in and risks related to: obtaining approval for this planned collaboration; </font></div><div><br></div><div></div><hr style="page-break-after:always"><div></div><div><br></div><div style="line-height:138%;padding-bottom:8px;padding-top:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">research and development efforts related to the collaboration programs; the possibility that results of clinical trials may be unsuccessful or insufficient to meet applicable regulatory standards or warrant continued development; other market or economic factors; unanticipated delays; each company&#8217;s ability to compete against parties with greater financial or other resources; greater than expected expenses; and such other risks detailed from time to time in each company&#8217;s reports filed with the Securities and Exchange Commission, including the Form 10-Q for the quarter ended June 30, 2017 filed by each company. Each party disclaims any intent or obligation to update these forward-looking statements.</font></div><div style="line-height:138%;padding-bottom:8px;padding-top:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">MacroGenics&#8217; Cautionary Note on Forward-Looking Statements</font></div><div style="line-height:138%;padding-bottom:8px;padding-top:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Any statements in this press release about future expectations, plans and prospects for MacroGenics, including statements about MacroGenics&#8217; strategy, future operations, clinical development of MacroGenics&#8217; therapeutic candidates, milestone or opt-in payments from MacroGenics&#8217; collaborators, MacroGenics&#8217; anticipated milestones and future expectations and plans and prospects for MacroGenics and other statements containing the words "subject to", "believe", "anticipate", "plan", "expect", "intend", "estimate", "project", "may", "will", "should", "would", "could", "can", the negatives thereof, variations thereon and similar expressions, or by discussions of strategy constitute forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including: the uncertainties inherent in the initiation and enrollment of future clinical trials, expectations of expanding ongoing clinical trials, availability and timing of data from ongoing clinical trials, expectations for regulatory approvals, other matters that could affect the availability or commercial potential of MacroGenics&#8217; product candidates and other risks described in MacroGenics&#8217; filings with the Securities and Exchange Commission. In addition, the forward-looking statements included in this press release represent MacroGenics&#8217; views only as of the date hereof. MacroGenics anticipates that subsequent events and developments will cause MacroGenics&#8217; views to change. However, while MacroGenics may elect to update these forward-looking statements at some point in the future, MacroGenics specifically disclaims any obligation to do so, except as may be required by law. These forward-looking statements should not be relied upon as representing MacroGenics&#8217; views as of any date subsequent to the date hereof.</font></div><div style="line-height:138%;padding-bottom:8px;padding-top:6px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"># # #</font></div><div style="line-height:138%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:138%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;text-decoration:underline;">Incyte Contacts:</font></div><div style="line-height:138%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:138%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Investors</font></div><div style="line-height:138%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Michael Booth, DPhil</font></div><div style="line-height:138%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">+1 302 498 5914</font></div><div style="line-height:138%;text-align:left;font-size:11pt;"><a style="font-family:inherit;font-size:11pt;color:#0000ff;text-decoration:underline;" href="#"><font style="font-family:inherit;font-size:11pt;color:#0000ff;text-decoration:underline;">mbooth@incyte.com</font></a></div><div style="line-height:138%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:138%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Media</font></div><div style="line-height:138%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Catalina Loveman</font></div><div style="line-height:138%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">+1 302 498 6171</font></div><div style="line-height:138%;text-align:left;font-size:11pt;"><a style="font-family:inherit;font-size:11pt;color:#0000ff;text-decoration:underline;" href="#"><font style="font-family:inherit;font-size:11pt;color:#0000ff;text-decoration:underline;">cloveman@incyte.com</font></a></div><div style="line-height:138%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:138%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;text-decoration:underline;">MacroGenics Contacts: </font></div><div style="line-height:138%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:138%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Investors</font></div><div style="line-height:138%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Jim Karrels</font></div><div><br></div><div></div><hr style="page-break-after:always"><div></div><div><br></div><div style="line-height:138%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">+1 301-251-5172</font></div><div style="line-height:138%;text-align:left;font-size:11pt;"><a style="font-family:inherit;font-size:11pt;color:#0000ff;text-decoration:underline;" href="#"><font style="font-family:inherit;font-size:11pt;color:#0000ff;text-decoration:underline;">info@macrogenics.com</font></a><font style="font-family:inherit;font-size:10pt;">&#32;</font></div><div style="line-height:138%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:138%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Media</font></div><div style="line-height:138%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Karen Sharma</font></div><div style="line-height:138%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">+1 781-235-3060</font></div><div style="line-height:138%;text-align:left;font-size:11pt;"><a style="font-family:inherit;font-size:11pt;color:#0000ff;text-decoration:underline;" href="#"><font style="font-family:inherit;font-size:11pt;color:#0000ff;text-decoration:underline;">ksharma@macbiocom.com</font></a><font style="font-family:inherit;font-size:10pt;">&#32;</font></div><div><br></div><div></div>	</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>exhibit991pressreleas_image1.jpg
<TEXT>
begin 644 exhibit991pressreleas_image1.jpg
M_]C_X  02D9)1@ ! 0$ W #<  #_VP!#  (! 0(! 0(" @(" @(" P4# P,#
M P8$! ,%!P8'!P<&!P<("0L)" @*" <'"@T*"@L,# P,!PD.#PT,#@L,# S_
MVP!# 0(" @,# P8# P8," <(# P,# P,# P,# P,# P,# P,# P,# P,# P,
M# P,# P,# P,# P,# P,# P,# P,# S_P  1" "^ 58# 2(  A$! Q$!_\0
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M'H.22 "0 >>_ME?M,Q_ 7P/]ETVXA_X2C6$*V497>;5.C7##I@=%#<,W9@K
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MW[1%U;^+;S5M6M;B;??QRS-(FHP-PMS!N.W< HQTQL,9*X('W+X.\8Z;X_\
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M/2/"MQ-#QY4]W>B)SZ[HU5A^3_X5Y5^V=\49OB)\;-1M5DD_L[P_(VGV\1R
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MCI7U9\8?B_H/P'^'M[XF\27,EKI.GF-97CB,KDNZHH55Y)+,.G09/0&O$O\
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MI]O?!)I->U)[N_P3&'3+33 8^[E0X&.^*^F/^"B_'P2TG_L-P_\ HBXKD_\
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M+][=S'\ >!--^&7@?2_#NCPM;Z7H]LEI;(6W,J*,#)[D]2>Y-?.'B[_@D/\
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MTK\6\:OX66?]A,/R9^B>''\3&?\ 7F7Z'W%1117[<?FX4444 %%%% !1110
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M@%%%%2 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
+%%%% !1110!__]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>4
<FILENAME>exhibit991pressreleasimage2.jpg
<TEXT>
begin 644 exhibit991pressreleasimage2.jpg
M_]C_X  02D9)1@ ! 0$ D "0  #_X1#R17AI9@  34T *@    @ ! $[  (
M   -   (2H=I  0    !   (6)R=  $    :   0T.H<  <   @,    /@
M   <Z@    @
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M                                                 %-M:71H+"!'
M97)R:0    60 P "    %   $*:0!  "    %   $+J2D0 "     S,X  "2
MD@ "     S,X  #J'  '   (#   ")H     '.H    (
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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MDH^['\04.K(X+>&U@2&UBCAB086.-0JJ/0 =*DHHKS2PHHHH **** "BBB@
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M *9965MIMC#9V,*P6\"!(XT& H':IZ6)Q$J\NR6R"*L%%%%<I04444 %%%%
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M'[WXCTKQ3X>^%6\7^-+33W5C:H?.NF':-<9'XG _&OK6-%BC6.-0J* JJ!P
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M ()G)W=D>U_!7PE_PC_@U=0NH]M]J@$S;ARD7\"_D=WX^U>CTBJ$4*H"J!@
M#@"EKP:U5U:CG+J:I65CD?BCK']C?#?59E;;+/%]FCQU+2';Q^!)_"O.M2^
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M5V5-5N_)@\I#^\D&/H*@TBRY^T2#I]W_ !J&W@DU"Z,DGKECZ#TK<50BA5&
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M<XTX\TG9";25V2SSI;Q%Y#@#MW-9 $VIW6XY5!T'91_C3XX)]2E$LQVIV_\
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MV7J*JKJE@_W+ZV;Z2K_C0VJ6"_>O;<?]M5_QH]M2_F7WAS1[EJBLY]>TQ/\
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,* "BBB@!:*** /_9

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
